These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27920517)

  • 1. Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone.
    Tamura T; Satoh H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2909-2911. PubMed ID: 27920517
    [No Abstract]   [Full Text] [Related]  

  • 2. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do we need three players in COPD treatment?
    Maestrelli P; Mason P; Costa F; Paggiaro P
    Respiration; 2013; 86(4):275-6. PubMed ID: 23988429
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF; Timmer W; Sagkriotis A; Viel K
    Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is salmeterol/fluticasone propionate equivalent to tiotropium bromide in the treatment of COPD?
    Gillissen A
    Am J Respir Crit Care Med; 2008 Jul; 178(1):105; author reply 106-7. PubMed ID: 18565963
    [No Abstract]   [Full Text] [Related]  

  • 6. Tiotropium versus salmeterol in COPD.
    Lloret-Linares C; Bergmann JF
    N Engl J Med; 2011 Jun; 364(26):2552-3; author reply 2553-4. PubMed ID: 21714656
    [No Abstract]   [Full Text] [Related]  

  • 7. Tiotropium versus salmeterol in COPD.
    Restrick L; Stern M; Baxter N
    N Engl J Med; 2011 Jun; 364(26):2552; author reply 2553-4. PubMed ID: 21714657
    [No Abstract]   [Full Text] [Related]  

  • 8. Tiotropium versus salmeterol in COPD.
    Schembri S
    N Engl J Med; 2011 Jun; 364(26):2553; author reply 2553-4. PubMed ID: 21714655
    [No Abstract]   [Full Text] [Related]  

  • 9. Tiotropium versus salmeterol in COPD.
    Oba Y
    N Engl J Med; 2011 Jun; 364(26):2553; author reply 2553-4. PubMed ID: 21714654
    [No Abstract]   [Full Text] [Related]  

  • 10. Stepping down therapy in COPD.
    Reilly JJ
    N Engl J Med; 2014 Oct; 371(14):1340-1. PubMed ID: 25196116
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED; van Dyk M; Sagriotis A
    Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
    Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment step down should be avoided at entry in COPD therapeutic trials.
    Marchand E
    Am J Respir Crit Care Med; 2008 Jul; 178(1):105-6; author reply 106-7. PubMed ID: 18565962
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients with COPD: a comparison of the INSPIRE and TORCH studies.
    Middleton PG
    Am J Respir Crit Care Med; 2008 Jul; 178(1):106; author reply 106-7. PubMed ID: 18565964
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease.
    Cramer JA; Bradley-Kennedy C; Scalera A
    Can Respir J; 2007; 14(1):25-9. PubMed ID: 17315055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
    Ismaila A; Corriveau D; Vaillancourt J; Parsons D; Dalal A; Su Z; Sampalis JS
    Curr Med Res Opin; 2014 Jul; 30(7):1427-36. PubMed ID: 24666181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient management of severe COPD.
    Singh S; Loke YK; Furberg CD
    N Engl J Med; 2010 Jul; 363(5):493-4; author reply 494-5. PubMed ID: 20666630
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenetics of COPD: a role for the β2-adrenergic receptor gene?
    Jensen CS; Dahl M
    Lancet Respir Med; 2014 Jan; 2(1):3-4. PubMed ID: 24461881
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic obstructive pulmonary disease megatrials: taking the results into office practice.
    Stoloff SW
    Am J Med Sci; 2011 Aug; 342(2):160-7. PubMed ID: 21512392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.